Sanofi pledges stable 2016 earnings

By Matthias Blamont and Noëlle Mennella PARIS (Reuters) - Sanofi said it expected stable earnings per share this year after reporting lower fourth-quarter income on Tuesday, hurt by declining sales of diabetes and cancer treatments and other prescription drugs. The French drugmaker, which is in the midst of a reorganisation to address falling sales of its best-selling insulin drug Lantus, said sales of its next-generation insulin treatment Toujeo launched last year doubled in the fourth qua